GlassScriptPhysician profile
Faisal Zahiruddin
NPI 1467743716
$4,704.81
in general payments reported to CMS, 2019-2025
35 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $34.20 · 2021: $97.75 · 2022: $289 · 2023: $631 · 2024: $1,436 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $568.05 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $561.62 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $553.76 | 2023-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $489.72 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.10 | 2021-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $248.84 | 2022-2025 | Tezspire, Breztri |
| Shionogi INC | $212.01 | 2023-2025 | Fetroja |
| Grifols USA, LLC | $207.55 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $163.71 | 2024-2025 | Glassia, Aralast |
| Regeneron Healthcare Solutions, INC. | $135.94 | 2024-2025 | Dupixent |
| Abbvie INC. | $127.86 | 2022-2025 | Avycaz |
| Eisai INC. | $125.00 | 2019 | |
| Astellas Pharma US INC | $101.72 | 2019-2025 | Cresemba |
| Mylan Specialty L.P. | $95.25 | 2024 | Yupelri |
| Viatris Specialty LLC | $90.61 | 2025 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $58.69 | 2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $53.47 | 2024-2025 | |
| Sandoz INC. | $50.22 | 2020-2023 | Treprostinil |
| Pfizer INC. | $45.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $41.79 | 2024-2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $40.08 | 2023-2025 | Acthar |
| Genzyme Corporation | $40.06 | 2023-2024 | |
| Tactile Systems Technology INC | $32.58 | 2025 | Nimbl, Flexitouch Plus |
| 3b Medical, INC. | $26.48 | 2023 | Luna |
| Alcresta Therapeutics, INC. | $20.63 | 2024 | Relizorb |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2024 | |
| Biogen, INC. | $19.12 | 2022 | |
| Pharming Healthcare, INC. | $18.39 | 2024 | Ruconest |
| Ani Pharmaceuticals, INC. | $17.55 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $17.32 | 2024 | Ultomiris |
| Johnson & Johnson Health Care Systems INC. | $16.95 | 2024 | Uptravi, Opsumit |
| Inogen, INC. | $16.41 | 2025 | |
| Optinose US, INC. | $15.58 | 2025 | |
| Resmed Corp | $15.05 | 2023 | |
| Philips North America LLC | $14.34 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Zahiruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.